RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
Fiche publication
Date publication
décembre 2019
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KIM Stephano, Mme HENRIQUES Julie
Tous les auteurs :
Lucidarme O, Wagner M, Gillard P, Kim S, Bachet JB, Rousseau B, Mazard T, Louvet C, Chibaudel B, Cohen R, Garcia-Larnicol ML, Gobert A, Henriques J, André T
Lien Pubmed
Résumé
To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib according to RECIST 1.1, Choi, and modified Choi (mChoi) criteria in patients with metastatic colorectal cancer (mCRC).
Mots clés
Colorectal cancer, Computed tomography, Tumor response
Référence
Cancer Imaging. 2019 12 9;19(1):85